News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results
Genel Energy PLC: Results of Annual General Meeting 8 May 2025
Genel Energy PLC: Results of Annual General Meeting 8 May 2025
Genel Energy PLC: Trading and operations update Q1 2025
Genel Energy PLC: Trading and operations update Q1 2025
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc